What does this research mean for the field?

Physiologically based pharmacokinetic modeling demonstrates that standard ceftriaxone dosing regimens in pregnant women result in reduced pharmacodynamic target attainment, indicating a need to reconsider current dosing strategies for conditions such as maternal syphilis. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

This research aims to develop a pharmacokinetic and pharmacodynamic model for ceftriaxone dosing in pregnant women.

May 16, 2026

Physiologically Based Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Analysis for Ceftriaxone Dosing in Pregnant Women: Model Development and Clinical Applications

Key Points

This research aims to develop a pharmacokinetic and pharmacodynamic model for ceftriaxone dosing in pregnant women.
Developed a modeling framework to quantify pharmacodynamic margins for ceftriaxone dosing.
Analyzed dosing strategies under standard regimens of 1 g and 2 g.
Evaluated implications for precision medicine in obstetric pharmacotherapy.
Established breakpoint reduction from 2.81 to 1.75 µg/mL at 1 g q.d. dose.
Reduced breakpoint from 5.61 to 3.50 µg/mL at 2 g q.d. dose.
Highlighted the need for revising pregnancy dosing strategies based on pharmacodynamic analysis.

Abstract

breakpoint (2.81→1.75 µg/mL at 1 g q.d.; 5.61→3.50 µg/mL at 2 g q.d.), quantifying the pharmacodynamic margin under standard regimens. This transparent, reproducible modeling framework provides quantitative support for reconsidering pregnancy dosing strategies and advances precision medicine approaches in obstetric pharmacotherapy during the ongoing maternal syphilis public health crisis.

AI से पूछें

Bookmark